The Value of Self-Care in Public Health: Insights and Implications for Europe

By Rene Pretorius

July 2, 2025

self-care public health

Summary
Self-care in public health is a critical pillar of public health in Europe. It enables individuals to manage minor ailments independently while easing pressure on healthcare systems. By using non-prescription medicines, devices, and supplements, self-care cuts costs, saves time, and boosts productivity. Evidence shows that the value of self-care in public health amounts to annual savings of €36 billion and averted productivity losses of €10 billion.

Key Insights
Reported study findings highlight self-care’s economic and social value. Europe avoids €36 billion yearly by managing 1.2 billion minor health issues through self-care. This includes €26 billion in medical expenses and €10 billion in productivity losses. Self-care also reduces GP workloads. It equals needing 120,000 extra doctors or 2.4 more hours daily for current practitioners. Consumer behavior is shifting toward prevention. 84% take preventive measures, and 67% spend over €21 monthly on health aids.

Background Context
Research shows self-care’s role in tackling healthcare challenges. The AESGP notes it empowers individuals with low-cost solutions for minor ailments. EU eHealth initiatives improve access to electronic records. The eHealth score reached 83% in 2024, supporting self-care goals.

Implications
For health economics, self-care offers a scalable, cost-effective solution. It helps strained systems as populations age and chronic diseases rise. Stronger policies could optimize resources, letting providers focus on complex cases. Public health efforts can align with preventive trends, reducing reliance on costly interventions. Barriers like uneven regulations and education gaps may limit uptake. Future steps include digital health tools to enhance self-care, matching EU digital goals.

Reference url

Recent Posts

pharmaceutical innovation ROI
Shifting Perspectives on Pharmaceutical Innovation ROI as Socioeconomic Investment

By João L. Carapinha

June 24, 2026

Pharmaceutical innovation ROI is shifting from a narrow budget metric to a powerful indicator of societal return. Between 2014 and 2024, a 3.1-year rise in utilization-weighted mean drug vintage across 29 European countries prevented 1.83 million years of life lost before age 85 and saved 20.9 mi...
pharmaceutical innovation benefits
Pharmaceutical Innovation Benefits Driving Socioeconomic Returns in Europe

By João L. Carapinha

June 23, 2026

Pharmaceutical innovation benefits extend well beyond clinical gains, delivering €5.67 in socioeconomic value for every additional euro spent on newer therapies across 29 European countries from 2014 to 2024. By reducing premature mortality, cutting hospital stays, and increasing workforce partic...
Teplizumab Type 1 Diabetes
Recommendation for Teplizumab Type 1 Diabetes Routine Use

By João L. Carapinha

June 23, 2026

Teplizumab for Type 1 Diabetes now has a clear route to routine NHS use after NICE recommended the therapy for delaying progression from stage 2 to stage 3 disease in people aged 8 and older. The decision, dependent on a confidential commercial discount, offers families more time before insulin d...